Ruxolitinib deuterated

Drug Profile

Ruxolitinib deuterated

Alternative Names: CTP-543; deuterated ruxolitinib; Deuterium modified ruxolitinib - Concert Pharmaceuticals

Latest Information Update: 20 Dec 2016

Price : $50

At a glance

  • Originator Concert Pharmaceuticals
  • Class 2 ring heterocyclic compounds; Cyclopentanes; Nitriles; Organic deuterium compounds; Pyrazoles; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alopecia areata

Most Recent Events

  • 14 Dec 2016 Adverse events and pharmacokinetics data from a phase I trial in healthy volunteers released by Concert Pharmaceuticals
  • 14 Dec 2016 Concert Pharmaceuticals completes a phase I trial in Alopecia areata (In volunteers) in Australia , NCT02777008)
  • 01 Nov 2016 Phase-I clinical trials in Alopecia areata (In volunteers) in USA (PO) (NCT02960945)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top